Antimicrobial, anti-TB, anticancer and anti-HIV evaluation of new s-triazine-based heterocycles

Future Medicinal Chemistry

Volumn 4, Issue 9, 2012, Pages 1053-1065

  Patel, Rahul V ^a   Kumari, Premlata ^a   Rajani, Dhanji P ^b   Pannecouque, Christophe ^c   De Clercq, Erik ^c   Chikhalia, Kishor H ^d  

^a SARDAR VALLABHBHAI NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^b Microcare Laboratory   (India)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d GUJARAT UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4,6 TRICHLORO 1,3,5 TRIAZINE; 4 [4 (4 ACETYL PIPERAZIN 1 YL) 6 (6 BROMO QUINOLIN 4 YLOXY) 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (4 BENZHYDRYL PIPERAZIN 1 YL) 6 (6 BROMO QUINOLIN 4 YLOXY) 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (4 BENZYL PIPERAZIN 1 YL) 6 (6 BROMO QUINOLIN 4 YLOXY) 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (4 BENZYL PIPERAZIN 1 YL) 6 (6 BROMO QUINOLIN 4 YLOXY) 1,3,5 TRIAZIN 2YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 (2 FLUORO PHENYL) PIPERIDIN 1 YL) 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 (3,5 DIMETHYL PIPERIDIN 1 YL) 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 (4 ETHYL PIPERAZIN 1 YL)] 1,3,5 TRIAZIN 2; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 (4 ISOPROPYL PIPERAZIN 1 YL) 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 (4 PHENYL PIPERAZIN 1 YL) 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 (4 PYRIDIN 2 YL PIPERAZIN 1 YL) 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 (4 PYRIMIDIN 2 YL PIPERAZIN 1 YL) 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 [4 (2 CHLOROPHENYL) PIPERAZIN 1 YL] 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 [4 (2,3 CHLOROPHENYL) PIPERAZIN 1 YL] 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 [4 (2,3,4 TRIMETHOXY BENZYL)PIPERAZIN 1 YL] 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 [4 (3 TRIFLUOROMETHYL PHENYL) PIPERAZIN 1 YL] 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 [4 (4 FLUORO PHENYL) PIPERAZIN 1 YL] 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 [4 (4 METHOXY PHENYL)PIPERAZIN 1 YL] 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 [4 CHLORO PHENYL)PHENYL METHYL]PIPERIDIN 1 YL) 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 MORPHOLIN 4 YL 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; 4 [4 (6 BROMO QUINOLIN 4 YLOXY) 6 PIPERIDIN 1 YL 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL-BENZONITRIL; 4 [4 (6 BROMOQUINOLIN 4 YLOXY) 6 CHLORO 1,3,5 TRIAZIN 2 YLAMINO] 2 TRIFLUOROMETHYL BENZONITRILE; BEDAQUILINE; BICALUTAMIDE; CIPROFLOXACIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; QUINOLONE DERIVATIVE; TRIAZINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER MORTALITY; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG DEVELOPMENT; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FINITE ELEMENT ANALYSIS; FLUORINE NUCLEAR MAGNETIC RESONANCE; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; MICROORGANISM; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; PUBLIC HEALTH; TUBERCULOSIS; VIRUS STRAIN; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; ANTITUBERCULAR AGENTS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICROBIAL SENSITIVITY TESTS; SPECTROPHOTOMETRY, INFRARED; TRIAZINES;

EID: 84862529315     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.57     Document Type: Article

References (51)

1. Nathan C. Antibiotics at the crossroads. Nature 431, 899-902 (2004). (Pubitemid 39434399)
2. Raviglione MC. The TB epidemic from 1992 to 2002. Tuberculosis 83, 4-14 (2003). (Pubitemid 36683544)
3. Diaz HG, Foster LA, Mushrush D, Vaz ADN. Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis. Biochem. Pharm. 61, 1463-1470 (2001). (Pubitemid 32476901)
4. Lourenc MCS, Grinsztejn B, Fandinho-Montes FCO. Genotypic patterns of multiple isolates of M. tuberculosis from tuberculous HIV patients. Trop. Med. Int. Health 5, 488-494 (2000). (Pubitemid 30622527)
5. Long R. Drug-resistant tuberculosis. Can. Med. Assoc. J. 163, 425-428 (2000).
6. Filler R, Saha R. Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights. Future Med. Chem. 1, 777-791 (2009).
7. Schellhammer PF. An evaluation of bicalutamide in the treatment of prostate cancer. Expert Opin. Pharmacother. 3, 1313-1328 (2002). (Pubitemid 34966046)
8. Giri R, Goodell JR, Xing C et al. Synthesis and cancer cell cytotoxicity of substituted xanthenes. Bioorg. Med. Chem. 15, 1456-1463 (2010).
9. Hu K, Yang ZH, Pan SS, Xu HJ, Ren J. Synthesis and antitumor activity of liquiritigenin thiosemicarbazone derivatives. Eur. J. Med. Chem. 45, 3453-3458 (2010).
10. Shallal HM, Russu WA. Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. Eur. J. Med. Chem. 46, 2043-2057 (2011).
11. Mahajan DH, Pannecouque C, De Clercq E. Synthesis and studies of new 2-(coumarin-4-yloxy)-4,6-(substituted)-s-triazine derivatives as potential anti-HIV agents. Arch. Pharm. Chem. Life Sci. 342, 281-290 (2009).
12. Chikhalia KH, Patel MJ. Design, synthesis and evaluation of some 1,3,5-triazinyl urea and thiourea derivatives as antimicrobial agents. J. Enzym. Inhib. Med. Chem. 24, 960-966 (2009).
13. Patel DH, Chikhalia KH, Shah NK, Patel DP, Kaswala PB, Buha VM. Synthesis and antimicrobial studies of s-triazine based heterocycles. J. Enzyme Inhib. Med. Chem. 25, 121-125 (2010).
14. Zhou C, Min J, Liu Z et al. Synthesis and biological evaluation of novel 1,3,5-triazine derivatives as antimicrobial agents. Bioorg. Med. Chem. Lett. 18, 1308-1311 (2008). (Pubitemid 351226548)
15. Srinivas K, Srinivas U, Bhanuprakash K, Harakishore K, Murthy USN, Jayathirtha RV. Synthesis and antibacterial activity of various substituted s-triazines. Eur. J. Med. Chem. 41, 1240-1246 (2006). (Pubitemid 44666218)
16. Alessandro B, Gorka JB, Mhairi LS, Vanessa Y, Reto B, Michael PB. Design and synthesis of a series of melamine-based nitroheterocycles with activity against trypanosomatid parasites. J. Med. Chem. 48, 5570-5579 (2005).
17. Menicagli R, Samaritani S, Signore G, Vaglini F, Dalla Via L. In vitro cytotoxic activities of 2-alkyl-4,6-diheteroalkyl-1,3,5-triazines: new molecules in anticancer research. J. Med. Chem. 47, 4649-4652 (2004). (Pubitemid 39195555)
18. Garaj V, Puccetti L, Fasolis G et al. Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg. Med. Chem. Lett. 15, 3102-3108 (2005). (Pubitemid 40755204)
19. Melato S, Prosperi D, Coghi P, Basilico N, Monti D. A combinatorial approach to 2,4,6-trisubstituted triazines with potent antimalarial activity: Combining conventional synthesis and microwave-assistance. ChemMedChem 3, 873-876 (2008).
20. Xiong YZ, Chen FE, Balzarini J, De Clercq E, Pannecouque C. Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity. Eur. J. Med. Chem. 43, 1230-1236 (2008). (Pubitemid 351734548)
21. Kerns RJ, Rybak MJ, Kaatz GW. Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of Staphylococcus aureus. Bioorg. Med. Chem. Lett. 13, 2109-2112 (2003). (Pubitemid 36694285)
22. Singh KK, Joshi SC, Mathela CS. Synthesis and in vitro antibacterial activity of N-alkyl and N-aryl piperazine derivatives. Ind. J. Chem. 50, 196-200 (2011).
23. Banerjee D, Yogeeswari P, Bhat P, Thomas A, Srividya M, Sriram D. Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection. Eur. J. Med. Chem. 46, 106-121 (2010).
24. Upadhayaya RS, Sinha N, Jain S, Kishore N, Chandra R, Arora SK. Optically active antifungal azoles: synthesis and antifungal activity of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-{2[4-aryl-piperazin-1-yl]-ethyl} -tetrazol-2-yl/1-yl)-1-[1,2,4]-triazol-1-yl-butan-2-ol.Bioorg. Med. Chem. 12, 2225-2238 (2004). (Pubitemid 38471710)
25. Upadhayaya RS, Vandavasi JK, Kardile RA. Novel quinoline and naphthalene derivatives as potent antimycobacterial agents. Eur. J. Med. Chem. 45, 1854-1867 (2010).
26. Kumar CS, Vinaya K, Chandra JN et al. Synthesis and antimicrobial studies of novel 1-benzhydryl-piperazine sulfonamide and carboxamide derivatives. J. Enzyme Inhib. Med. Chem. 23, 462-469 (2008).
27. Al-Turkistani AA, Al-Deeb OA, El-Brollosy NR, El-Emam AA. Synthesis and antimicrobial activity of some novel 5-alkyl-6-substituted uracils and related derivatives. Molecules 16, 4764-4774 (2011).
28. Sunduru N, Gupta L, Chaturvedi V, Dwivedi R, Sinha S, Chauhan PMS. Discovery of new 1,3,5-triazine scaffolds with potent activity against Mycobacterium tuberculosis H37Rv. Eur. J. Med. Chem. 45, 3335-3345 (2010).
29. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005). (Pubitemid 40116230)
30. Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52, 2831-2835 (2008).
31. Upadhayaya RS, Lahore SV, Sayyed AY, Dixit SS, Shinde PD, Chattopadhyaya J. Conformationally-constrained indeno[2,1-c]quinolines-a new class of anti-mycobacterial agents. Org. Biomol. Chem. 8, 2180-2197 (2010).
32. Upadhayaya RS, Shinde PD, Sayyed AY et al. Synthesis and structure of azole-fused indeno[2,1-c]quinolines and their anti-mycobacterial properties. Org. Biomol. Chem. 8, 5661-5673 (2010).
33. Upadhayaya RS, Shinde PD, Kadam SA et al. Synthesis and antimycobacterial activity of prodrugs of indeno[2,1-c]quinoline derivatives. Eur. J. Med. Chem. 46, 1306-1324 (2011).
34. Patel DK, Patel RV, Kumari P, Patel NB. In vitro antimicrobial assessment of coumarin based s-triazinyl piperazines. Med. Chem. Res. doi:10.1007/s00044- 011-9676-3 (2011) (Epub ahead of print).
35. Patel RV, Kumari P, Chikhalia KH. Novel s-triazinyl piperazines: design, synthesis, characterization and anti-microbial activity. Arch. Appl. Sci. Res. 2, (2010) 232-240.
36. Patel RV, Kumari P, Chikhalia KH. Fluorinated s-triazinyl piperazines as antimicrobial agents. Z. Naturforsch. C. 66, 341-345 (2011).
37. Patel RV, Kumari P, Rajani DP, Chikhalia KH. A new class of 2-(4-cyanophenyl amino)-4-(6-bromo-4-quinolinyloxy)-6-piperazinyl(piperidinyl)- 1,3,5-triazine analogues with antimicrobial/antimycobacterial activity. J. Enzyme Inhib. Med. Chem.27(3), 370-379 (2011).
38. Patel RV, Kumari P, Rajani DP, Chikhalia KH. Synthesis and studies of novel 2-(4-cyano-3-trifluoromethylphenyl amino)-4-(quinoline-4-yloxy)-6- (piperazinyl/piperidinyl)-s-triazines as potential antimicrobial, antimycobacterial and anticancer agents. Eur. J. Med. Chem. 46, 4354-4365 (2011).
39. Patel RV, Kumari P, Rajani DP, Chikhalia KH. Synthesis, characterization and pharmacological activities of 2-[4-cyano-(3-trifluoromethyl)phenyl amino)]-4-(4-quinoline/coumarin-4-yloxy)-6-(fluoropiperazinyl)-s-triazines. J. Fluorine Chem. 132, 617-627 (2011).
40. Xiong YZ, Chen FE, Balzarini J, De Clercq E, Pannecouque C. Non-nucleoside HIV-1 reverse transcriptase inhibitors: part 13: synthesis of fluorine-containing diaryltriazine derivatives for in vitro anti-HIV evaluation against wild-type strain. Chem. Biodiversity 6, 561-568 (2009).
41. Gillespie SH. Medical Microbiology-Illustrated. Butterworth Heinemann Ltd Oxford, UK, 234-247 (1994).
42. Hawkey PM, Lewis DA. Medical Bacteriology-a Practical Approach. Oxford University Press, Oxford, UK, 181-194 (1994).
43. Anargyros P, Astill DS, Lim IS. Comparison of improved BACTEC and Lowenstein-Jensen media for culture of mycobacteria from clinical specimens. J. Clin. Microbiol. 28, 1288-1291 (1990). (Pubitemid 20194420)
44. Isenberg HD. Clinical Microbiology Procedures Handbook, Volume 1. American Society for Microbiology, Washington, DC, USA (1992).
45. Vanicha V, Kanyawim K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 1, 1112-1116 (2006).
46. Pauwels R, Balzarini J, Baba M et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20, 309-321 (1988).
47. Pannecouque C, Daelemans D, De Clercq E. Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat. Protoc. 3(3), 427-434 (2008). (Pubitemid 351384256)
48. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224, 497-500 (1984). (Pubitemid 14134740)
49. Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983). (Pubitemid 13080157)
50. Miyoshi I, Taguchi H, Kobonishi I et al. Type C virus-producing cell lines derived from adult T cell leukemia. Gann Mono. Cancer Res. 28, 219-229 (1982).
51. Dandia A, Arya K, Sati M, Sarawgi P. Green chemical synthesis of fluorinated 1,3,5-triaryl-s-triazines in aqueous medium under microwaves as potential antifungal agents. J. Fluorine Chem. 125, 1273-1277 (2004).